Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - beclometasone dipropionate - pressurised inhalation, solution - 100 microgram(s) - glucocorticoids; beclometasone

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - beclometasone dipropionate - pressurised inhalation, solution - 200 microgram(s) - glucocorticoids; beclometasone

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - porcine lung surfactant - endotrachpulm inst, susp - 120 milligram(s) - lung surfactants; natural phospholipids

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - porcine lung surfactant - endotrachpulm inst, susp - 240 milligram/vial - lung surfactants; natural phospholipids

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - zopiclone - film-coated tablet - 3.75 milligram(s) - benzodiazepine related drugs; zopiclone

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - zopiclone - film-coated tablet - 7.5 milligram(s) - benzodiazepine related drugs; zopiclone

European Union - English - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - cangrelor - acute coronary syndrome; vascular surgical procedures - antithrombotic agents - kengrexal, co-administered with acetylsalicylic acid (asa), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (pci) who have not received an oral p2y12 inhibitor prior to the pci procedure and in whom oral therapy with p2y12 inhibitors is not feasible or desirable.

United States - English - NLM (National Library of Medicine)

chiesi usa, inc. - poractant alfa (unii: ke3u2023np) (poractant alfa - unii:ke3u2023np) - poractant alfa 80 mg in 1 ml - curosurf® (poractant alfa) intratracheal suspension is indicated for the rescue treatment of respiratory distress syndrome (rds) in premature infants.  curosurf reduces mortality and pneumothoraces associated with rds.  none. the safety and effectiveness of curosurf for the rescue treatment, including the reduction of mortality and pneumothoraces, of respiratory distress syndrome (rds) have been established in premature infants and the information on this use is discussed throughout the labeling. the safety and effectiveness of curosurf in the treatment of full term infants or older pediatric patients with respiratory failure has not been established.

United States - English - NLM (National Library of Medicine)

chiesi usa, inc. - zileuton (unii: v1l22wve2s) (zileuton - unii:v1l22wve2s) - zileuton 600 mg - zyflo is indicated for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. zyflo tablets are contraindicated in patients with: - active liver disease or transaminase elevations greater than or equal to three times the upper limit of normal (≥3xuln) (see precautions, hepatic ). - hypersensitivity to zileuton or any of its inactive ingredients.

Ireland - English - HPRA (Health Products Regulatory Authority)

chiesi limited - beclometasone dipropionate anhydrous; formoterol fumarate dihydrate - pressurised inhalation, solution - 100/6 microgram(s)